In:
Acta Haematologica, S. Karger AG, Vol. 124, No. 2 ( 2010), p. 92-97
Kurzfassung:
〈 i 〉 Background: 〈 /i 〉 This observational study was conducted to document the efficacy and safety of the use of micafungin (Mycamine) as an empirical antifungal agent in febrile neutropenic patients. 〈 i 〉 Methods: 〈 /i 〉 Micafungin was administered for sustained fever ( 〉 38.4°C) on days 3–5 following the initiation of empirical antibiotic therapy. The overall success rate and side effects were evaluated. 〈 i 〉 Results: 〈 /i 〉 A total of 47 patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome and lymphoma were enrolled in the study. The overall success rate of micafungin was 61.7% (29/47). A total of 3 patients (6.4%) experienced grade 3/4 elevations in their aspartate aminotransferase levels, and 10 patients (21%) experienced grade 3/4 hyperbilirubinemia, 9 of which resolved. Four patients died of septic shock. Younger patients ( 〈 50 years) and patients with acute lymphoblastic leukemia exhibited a better response to micafungin than other patients. Patients that were less profoundly neutropenic (≧0.05 × 10 〈 sup 〉 9 〈 /sup 〉 /l) also had a better response to micafungin, as did the patients who recovered from their fever or neutropenia. 〈 i 〉 Conclusion: 〈 /i 〉 Micafungin has an excellent efficacy (61.7%) and safety profile when used as an empirical antifungal agent in febrile neutropenic patients with hematological disorders.
Materialart:
Online-Ressource
ISSN:
0001-5792
,
1421-9662
Sprache:
Englisch
Verlag:
S. Karger AG
Publikationsdatum:
2010
ZDB Id:
1481888-7
ZDB Id:
80008-9
